Use access key #2 to skip to page content.
$39.75 -0.68 (-1.68%)
7/3/2008 1:00 PM

ImClone Systems, Inc. (IMCL)

CAPS Rating:
****

A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

View All Commentary (IMCL)

Recs

0

Avatar SapphireSeas (90.22) Submitted: 6/01/07 2:02 PM : Outperform Start Price: $41.51 IMCL Score: 13.70

One word - Erbitrux (hope I spelled that right). ImClone still building on early success, and clinicals are promising for even more potent oncology applications to come.

Report this Post Replies: 0 | Reply

Featured Broker Partners